Evaxion Biotech AS (EVAX)
4.18
+0.06
(+1.46%)
USD |
NASDAQ |
Apr 26, 16:00
4.13
-0.05
(-1.20%)
After-Hours: 20:00
Evaxion Biotech Cash from Financing (TTM)
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
| Date | Value |
|---|---|
| June 30, 2022 | 32.03M |
| March 31, 2022 | 32.29M |
| December 31, 2021 | 49.80M |
| September 30, 2021 | 27.53M |
| Date | Value |
|---|---|
| June 30, 2021 | 34.07M |
| March 31, 2021 | 34.09M |
| December 31, 2020 | 8.817M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
8.817M
Minimum
Dec 2020
49.80M
Maximum
Dec 2021
31.23M
Average
32.29M
Median
Mar 2022
Cash from Financing (TTM) Benchmarks
| Ascendis Pharma A/S | 145.39M |
| DBV Technologies SA | 6.767M |
| Cellectis SA | 36.24M |
| Adaptimmune Therapeutics PLC | 0.88M |
| Akari Therapeutics PLC | -- |